Abiopharma

🔍 Gould Brian (Executive)

Company: Enact Holdings, Inc. (ACT)

Report Date: 2026-06-18

Detailed Transactions and Holdings:

• Acquired 12 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,020.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2, F2
• Acquired 19 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,277.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4, F4
• Acquired 23 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-18 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,945.00 | transaction_form_type: 4 | Footnotes: F1, F3, F5, F5

Footnotes:

• F1: Each restricted stock unit will settle into shares of Issuer common stock on a 1:1 basis.
• F2: Restricted Stock Units vest and convert to Common Stock in three equal annual installments beginning on February 16, 2025.
• F3: Additional restricted stock units acquired pursuant to reinvestment terms in the restricted stock unit award agreement resulting from a quarterly dividend at $0.24 per share, paid on June 18, 2026.
• F4: Restricted Stock Units vest and convert to Common Stock in three equal annual installments beginning on February 21, 2026.
• F5: Restricted Stock Units vest and convert to Common Stock in three equal annual installments beginning on February 13, 2027.